Severe fever with thrombocytopenia syndrome (SFTS) is a disease with a high case fatality rate that is caused by infection with the recently identified tick-borne SFTS virus (SFTSV), for which there are no specific countermeasures. We examined the effects of ribavirin and mizoribine, which are nucleoside analogue drugs with broad antiviral activities, on SFTSV proliferation in vitro. When 3 cell lines were treated with these drugs before and during infection with a Chinese SFTSV strain, the 99z effective concentrations (EC 99 ) of ribavirin were 19-64 mg/ml (78-262 mM); in contrast, the EC 99 of mizoribine was ＞500 mg/ml (1,929 mM). Similar levels of inhibitory effects of ribavirin were observed with 4 Japanese SFTSV strains. However, when Vero cells were treated with ribavirin 3 days after inoculation, the inhibitory effect was dramatically decreased, indicating that ribavirin did not effectively reduce virus production in pre-infected cells. These results suggest that ribavirin could be used as postexposure prophylaxis for the prevention of SFTS.
INTRODUCTION
Severe fever with thrombocytopenia syndrome (SFTS) is a recently-identified disease characterized by fever, gastrointestinal symptoms, thrombocytopenia, leukopenia, and elevated levels of liver enzymes in peripheral blood (1, 2) . Multiple organ failure and disseminated intravascular coagulation are often observed in severe cases (3) . Its case fatality rate is approximately 12z (1) . The causative agent of the disease is the SFTS virus (SFTSV) (family: Bunyaviridae, genus: Phlebovirus), the discovery of which was reported in 2011 (1, 2) . Although sporadic outbreaks of the disease have been recently found in Japan and South Korea, retrospective studies have indicated the emergence of SFTS in Japan in 2005 and in China in 2006 (4) (5) (6) .
Epidemiology suggests that the transmission routes of SFTSV are tick bites and human-to-human transmission. The virus has been detected in several tick species including Haemaphysalis longicornis and Rhipicephalus microplus, which have been found in areas surrounding the places in which SFTS patients reside a substantial number of whom had a history of tick bites (1,2,7). Although not common, direct human-to-human transmission through close contact with virus-containing blood or excreta has also been reported (4, (8) (9) (10) (11) .
Ribavirin (1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), a guanosine analogue with broad antiviral activities, is effective in the treatment of Lassa fever (12) and hepatitis C when administered in combination with other drugs (13) . Ribavirin is also used in the treatment of Crimean-Congo hemorrhagic fever (CCHF) (14) ; however, its efficacy in CCHF treatment remains to be proven. Ribavirin exerts its antiviral effects through various mechanisms, including the reduction of viral RNA-dependent RNA polymerase activity, mutagenesis in the viral genome, inhibition of RNA capping, reduction of cellular inosine monophosphate dehydrogenase (IMPDH) activity, and modulation of the host immune response (15) . The drug has been used in the treatment of some SFTS patients, but at the time of use, its effect was unknown (4, 16) . Mizoribine (4-carbamoyl-1-b-Dribofuranosylimidazolium-5-olate) is an imidazole nucleoside that has been used as an immunosuppressive agent in Japan. Although mizoribine shows inhibitory effects in vitro against herpes simplex virus (17), respiratory syncytial virus (18) , influenza virus (19) , and severe acute respiratory syndrome virus (20) , there have been no reports on mizoribine usage or its effects with regard to SFTS or SFTSV.
In the present study, we examined the effects of ribavirin and mizoribine on SFTSV in vitro to clarify the potential of these drugs as countermeasures against SFTS. When ribavirin treatment was initiated before virus inoculation, SFTSV proliferation dramatically reduced, suggesting the prospective use of ribavirin as a post-exposure prophylactic.
MATERIALS AND METHODS

Cells and viruses:
Monkey kidney-derived Vero, human hepatoma-derived Huh7, and human osteosarcoma-derived U2OS cells were cultured at 379 C in DMEM (Sigma, St. Louis, MO, USA) supplemented with 5z heat-inactivated fetal calf serum (FCS) and antibiotics. Cells inoculated with SFTSV or Rift Valley fever virus (RVFV) were maintained in DMEM supplemented with 2z FCS and antibiotics. The Chinese SFTSV strain HB29 was provided by Drs. Mi-Fang Liang and De-Xin Li (National Institute for Viral Disease Control and Prevention, China). The Japanese SFTSV strains SPL004, SPL010, SPL030, and YG1 have been previously described (5) . Propagation of SFTSV and RVFV (MP-12) was performed with Vero cells.
Virus titration: SFTSV was serially diluted and inoculated onto Vero cells in quadruplicates. After 3 days of culture, cells were fixed with 10z formalin and permeabilized with 0.1z Triton-X100. Cells were subjected to incubation with rabbit anti-SFTSV nucleocapsid (N) protein (5) followed by further incubation with Alexa Fluor 488-labeled anti-rabbit IgG (H ＋ L) (Life Technologies, Gaithersburg, MD, USA). Observation was performed under a fluorescence microscope (BZ-9000, Keyence, Osaka, Japan), and viral titers were calculated as median tissue culture infectious dose per ml (TCID 50 /ml) using the Reed-Muench method (21) . The same protocol was applied for titration of RVFV, with mouse anti-RVFV N protein (clone G2-36) and Alexa Fluor 488-labeled anti-mouse IgG (H ＋ L) being used as primary and secondary antibodies, respectively.
Effects of drugs on virus/cell proliferation: Ribavirin and mizoribine (Kindly provided from Yamasa-Shouyu Co., Choshi, Japan) were dissolved in phosphatebuffered saline at a concentration of 100 mg/ml and, for treating cells, were further diluted with cell culture medium at indicated concentrations. A drug concentration of 0 mg/ml indicates the treatment of cells with cell culture medium containing no drugs. Cells were pretreated with ribavirin or mizoribine at indicated concentrations for 1 h. One hundred TCID 50 of SFTSV or RVFV was added to the culture without the removal of the drugs and then incubated for 3 days. Culture supernatants were harvested and subjected to virus titration.
To examine the cytotoxicity of the drugs, cells were cultured for 3 days in the presence or absence of the drugs without virus inoculation, and cell viability was measured using the cell proliferation reagent WST-1 (Roche, Penzberg, Germany) according to the manufacturer's protocol. Cell viability was calculated as follows: (absorbance of cells in the presence of the drug -absorbance of no cells in the presence of the drug)/(absorbance of cells in the absence of the drug -absorbance of no cells in the absence of the drug) × 100 (z).
Effects of ribavirin in SFTSV preinfected cells: Cells were inoculated with SFTSV (100 TCID 50 ) and cultured for 3 days, and then culture media were replaced with drug-containing media. After another 3 days of culture, supernatants were harvested and titrated.
Statistics: A paired t-test was used for statistical analysis of the drugs' effects.
RESULTS
Effects of ribavirin and mizoribine on SFTSV proliferation: Fig. 1 shows viral titers obtained from monkey Vero cells, which were inoculated with the Chinese SFTSV strain (HB29) in the presence of ribavirin or mizoribine (0, 4, 20, 100, and 500 mg/ml). Although statistically significant inhibitory effects (P ＜ 0.05) of ribavirin and mizoribine were observed at 20-500 mg/ml and 100-500 mg/ml, respectively, ribavirin showed a greater reduction of viral titers than mizoribine (Fig. 1A, B) . Ribavirin was also found to profoundly affect HB29 proliferation in 2 human cell lines, Huh7 and U2OS (Fig. 1C-F) . Reduction curves were used to calculate 99z effective concentrations (EC 99 ), the drug concentrations at which viral titers were reduced by 2 logs (Fig. 1) . The EC 99 of ribavirin, was 64 mg/ml (263 mM), 20 mg/ml (83 mM), and 19 mg/ml (78 mM) in Vero, Huh7, and U2OS cells, respectively. In contrast, no 99z inhibition was observed with mizoribine, even at the highest concentration of 500 mg/ml (1,929 mM; Table 1 ).
Similar results were obtained with the Japanese SFTSV strain SPL030 ( Table 1 ). The 3 additional Japanese strains (SPL004, SPL010, and YG1) were tested to further confirm the effects of ribavirin. Huh7 cells were inoculated with 100 TCID 50 of each strain in the presence of 20 mg/ml of ribavirin and cultured for 3 days. Titers of SPL004, SPL010, and YG1 strains were reduced by 1.83, 1.83, and 2.25 log(s), respectively.
Cytotoxicity was examined by measuring cell viability after cell culture in the presence of the drugs. As shown in Fig. 2, ＞60z viability was maintained in all 3 cell types, even at 500 mg/ml.
Effects of ribavirin on RVFV proliferation: To speculate on the potential effects of ribavirin on SFTS/ SFTSV in vivo, the drug's inhibitory effects on RVFV proliferation were examined. RVFV is another member of the Phlebovirus genus, for which both the in vitro and in vivo effects of ribavirin have been reported (22) (23) (24) . Ribavirin reduced RVFV proliferation in a dose-dependent manner (Fig. 1G) , and the EC 99 in Vero cells was 50 mg/ml (207 mM; Table 1 ).
Effects of ribavirin in SFTSV preinfected cells: We next examined the potential of ribavirin for reducing virus production from cells that had been previously infected with SFTSV. Vero cells were inoculated with SFTSV and cultured for 3 days (the culture period during which most inoculated cells became SFTSV-positive [data not shown]). Culture media were then replaced with ribavirin-containing media (0-500 mg/ml). After another 3 days of culture, supernatants were harvested and titrated. As shown in Fig. 3 , ribavirin displayed statistically significant effects at 100 and 500 mg/ml; however, the reduction at 500 mg/ml was only about 1 log.
DISCUSSION
In the presence of ribavirin, SFTSV proliferation was moderately reduced, and the inhibitory effects in in vitro experiments were not strain-specific ( Fig. 1 ; Table 
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Ribavirin Effects on SFTSV In Vitro 1; data not shown). Diversity among the nucleotide sequences of SFTSV strains reported from China, Japan, and South Korea is less than 5z (5,6), which suggests that ribavirin would likely show similar inhibitory effects against all SFTSV strains, regardless of areas from where the viruses have been isolated. Although both ribavirin and mizoribine have been shown to inhibit several viruses including herpes simplex virus, respiratory syncytial virus, influenza virus, and severe acute respiratory syndrome virus (17) (18) (19) (20) , mizoribine did not show an efficient inhibitory effect on SFTSV proliferation. The finding that effective doses of ribavirin against SFTSV were higher in Vero cells than in the other 2 cell lines (Table 1) is consistent with previous reports by Huffman et al. (25) and Peters et al. (23) , in which the impact of ribavirin on several DNA/RNA viruses was compared in several cell lines. Given that the known functions of mizoribine are the inhibition of inosine monophosphate synthetase and guanosine monophosphate synthetase (26) , other functions of ribavirin, such as viral polymerase inhibition, mutagenesis, RNA capping inhibition, and/or reduction of cellular IMPDH, might be critical in its effects on SFTSV proliferation.
To speculate on the potential effects of ribavirin on SFTS/SFTSV in vivo, the drug's inhibitory effects on RVFV proliferation (another member of the Phlebovirus genus) were examined in our assays and compared with those on SFTSV. Peters et al. reported that ribavirin at 23 mg/ml showed 2-log inhibition against RVFV in Vero cells (23) . In animal models, ribavirin treatment (75-100 mg/kg/day) led to a 60z-75z survival rate in RVFV-inoculated mice (22) (23) (24) , while it suppressed viremia in RVFV-infected monkeys (30 mg/kg/day, more than 2-log reduction of viral titers) (23) . In the present study, the EC 99 of ribavirin in Vero cells against SFTSV . Experiments were performed in triplicate and means ± standard deviation are shown. Fig. 3 Effects of ribavirin on SFTSV production from SFTSVpre-infected cells. Vero cells were inoculated with SFTSV and cultured for 3 days. Culture media were then replaced with ribavirin-containing media. After a further 3 days culture, supernatants were harvested and viral titers were determined. Results were obtained from 3 independent experiments. * , P ＜ 0.05.
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(64-104 mg/ml, 2-log inhibition) suggests that SFTSV may be slightly less sensitive to ribavirin than RVFV (Table 1) . However, because the impact of ribavirin in human cell lines occurred at 15-20 mg/ml (Table 1 ) and a single dose of ribavirin at 600-2,400 mg reached peak serum concentrations of 47-161 mM (equivalent to approximately 11-39 mg/ml) (27, 28) , the effects of ribavirin in vivo could be substantial. Recently, an animal model using interferon a/b receptor-knockout mice was reported in which SFTSV infection was fatal (29) . The model might be useful for understanding the pathogenesis of SFTS and for evaluating the in vivo effects of antiviral drugs, including ribavirin, against SFTS/SFTSV. In the present study, ribavirin added before virus inoculation inhibited SFTSV proliferation. In some SFTS cases, exposure to SFTSV can be recognized immediately (4, (8) (9) (10) (11) . Thus, suggesting that ribavirin could be an effective post-exposure prophylaxis that will minimize the severity of SFTS in cases where individuals are deemed to be at a high risk of SFTSV infection, such as in cases in which contaminated sharp instruments penetrate skin or in which an individual comes into close contact with the patient's blood or excreta.
Ribavirin did not show an effective reduction of virus production in pre-infected cells, when added 3 days after inoculation (Fig. 3) . This suggests that ribavirin has no effect on fully-infected cells or in patients in whom SFTSV has already expanded systemically. In SFTS patients, serum viral loads are very high on hospital admission, particularly in fatal cases (30, 31) . It is therefore unlikely that ribavirin would be effective in the treatment of patients who are already showing symptoms of SFTS. This corresponds with a report by Liu et al., which noted that neither fatality ratios nor blood laboratory test results of SFTS patients improved with ribavirin therapy (32) . However, in hepatitis C, combination therapies that include ribavirin (along with interferon and/or specific antiviral drugs) have been shown to be very effective, while the usage of ribavirin alone is less profound (13, 33) . As such, the possibility exists that ribavirin could be effective as a part of combination therapy in the treatment of SFTS patients.
